Pursuant to regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), we are enclosing herewith ....

INNOVA CAPTAB LIMITED Plot No. 320, Industrial Area, Phase-1, Panchkula, Pin-134113, Haryana, India. Phone: +91-172-4194500 11th August, 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Mumbai – 400001 Bandra Kurla Complex BSE Symbol: INNOVACAP Bandra (E), Mumbai – 400051 BSE Scrip Code: 544067 NSE Symbol: INNOVACAP Dear Sir/Madam, Subject: Press release Pursuant to regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”) we are enclosing herewith the press release issued by the Company on the unaudited financial results (standalone and consolidated) for the quarter ended 30th June, 2026. The Press Release will also be available on the website of the Company at www.innovacaptab.com. This is for your information and record. Thanking you, Yours faithfully, For Innova Captab Limited Neeharika Shukla Company Secretary and Compliance Officer Encl.: As above Registered Office - 1513, 15th Floor, Satra Plaza CHS Ltd. Plot No. 19&20, Sector-19D, Vashi, Navi Mumbai-400703, Maharashtra, India. CIN - L24246MH2005PLC150371, email - mail@innovacaptab.com INNOVA CAPTAB LIMITED Press Release Innova Captab Limited reported strong results for Q1 FY27, with Revenue from Operations at ₹ 470.9 crores and EBITDA at ₹ 75.1 crores Mumbai, 11th August, 2026: Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its unaudited financial results for the quarter ended June 30th, 2026. Consolidated Financial Summary: Particulars (₹ Crs.) Q1FY27 Q1FY26 YoY (%) FY26 Revenue from operations 470.9 351.5 34.0% 1,630.0 EBITDA 75.1 56.6 32.7% 250.3 EBITDA Margin 16.0% 16.1% (10 bps) 15.4% PAT 44.1 31.0 42.3% 140.9 Q1FY27 vs. Q1 FY26 Performance: • Revenue from Operations registered strong growth of 34.0% to ₹ 470.9 crores vs. ₹ 351.5 crores • Recorded EBITDA growth of 32.7% to ₹ 75.1 crores vs. ₹ 56.6 crores. EBITDA margin for the quarter was 16.0% • PAT for the quarter was ₹ 44.1 crores, registering growth of 42.3%. PAT margin was 9.4% Commenting on the company’s performance, Mr. Vinay Lohariwala, Managing Director, Innova Captab Limited, said “Innova Captab Limited delivered a strong start to FY27, with revenue and EBITDA growing by 34% and 33% YoY, respectively. The performance underscores the continued strength of our diversified business model, disciplined execution and sustained customer traction across both our CDMO Services & Products and Branded Generics businesses. Growth during the quarter was supported by steady order flows, a broader product portfolio and deeper engagement with existing and new customers. Our focus on operational excellence, manufacturing efficiency and quality continues to strengthen our competitive positioning and enables us to meet the evolving requirements of domestic and international markets. Our Jammu facility is witnessing a steady ramp-up, supported by increasing business from existing customers as well as the onboarding of new clients. We remain committed to strengthening our position as a trusted CDMO partner while expanding our branded generics footprint across key markets. With a clear strategic roadmap, disciplined capital allocation and timely execution, we are confident of sustaining growth while enhancing profitability and delivering long-term value for our stakeholders” About Innova Captab Limited Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company in India with a comprehensive business model and presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) business, the company provides an elaborate suit of pharmaceutical products to over 350 clients in India and key international markets. Apart from this, the company has strong direct presence across India and international markets with its Branded Generics Business. The company operates five state-of-the-art manufacturing facilities consisting of 9 independent blocks, accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA, PIC/s among others. For more details, please visit www.innovacaptab.com For more information, please contact: Company Details Investor Relations Advisors Innova Captab Ltd. Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 CIN: L24246MH2005PLC150371 Ms. Shaily Patwa/ Mr. Shrikant Sangani Mr. Lokesh Bhasin Email - shaily.p@sgapl.net /shrikant.sangani@sgapl.net Email Id – investors@innovacaptab.com Mobile No – 9819494608 / 9619595686 www.innovacaptab.com www.sgapl.net DISCLAIMER: Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.